Amneal raises FY 2023 guidance after Q3 prelim: rev $610-620M, adj EBITDA $150-155M

Amneal Pharmaceuticals, Inc.

2023-Q3 EPS reported $0.09 revenue$1,776,626,000

Net revenue prelim Q3 2023 $610-620M, up ~13% YoY.
Adjusted EBITDA $150-155M, up ~21% YoY; income before taxes $18-28M, substantially higher YoY.
Net leverage declined to ~4.6x from 5.3x at Dec 2022 due to higher profitability and debt reduction.
Full-year 2023 guidance raised; Co-CEOs cite momentum from generics, biosimilars, and AvKARE.
IPX203 for Parkinson's on track for potential 2024 launch.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amneal Pharmaceuticals, Inc. reported the third quarter ended September 30, 2023 results: revenue $610 million to $620 million. Guidance raised.

Period: the third quarter ended September 30, 2023
Revenue: $610 million to $620 million
Guidance: raised
Result: preliminary results

Exact text from the filing

report actual third quarter 2023 financial results on November 7, 2023. Unaudited Preliminary Financial Results for the Third Quarter Ended September 30, 2023 • Net revenue of $610 million to $620 million, an increase of approximately 13% compared to the third quarter of 2022 • Income before income taxes of $18 million to $28 million, which is substantially higher

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-23-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.